Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures

Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures
Researchers discovered how AB Science’s therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). The discovery could lead to better treatments for diseases where nucleoside analogues like Gemzar are used as therapy, such as in some viral diseases and cancers. The results from the preclinical study were published in the article, “Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology,” in the journal Nature Communications. The researchers found that masitinib acts on an enzyme called human deoxycytidine kinase (dCK) and activates it. In turn, dCK modifies nucleoside analogues, Gemzar among them, making them more potent. Masitinib can promote the activity of nucleoside analogue agents in fighting cancer. Therefore, it can potentially be used to reduce the toxicity of dCK-dependent drugs by maintaining drug effectiveness at lower doses or by counteracting drug resistance in tumors. “These findings represent a novel mechanism of action for masitinib that is of relevance to its oncology development program," Patrice Dubreuil, director of research at the INSERM Center for Cancer Research of Marseille and senior author of the study, said in a press release. "This property of masitinib is of potential clinical benefit through either reducing toxicity of dCK-associated therapeutic agents by maintaining therapeutic efficiency at lo
Subscribe or to access all post and page content.

One comment

  1. Fitoussi says:

    Thank you so much for your accurate and impartial information

    This will give hope to all the patients. This is a true progress for science


    Paris, France

Leave a Comment

Your email address will not be published. Required fields are marked *